Envoy Medical, Inc. (COCH): Nasdaq/NYSE listing notice — Envoy Medical receives Nasdaq extension to November 16, 2026 to cure bid price deficiency

Envoy Medical, Inc.

Company received Nasdaq notice granting additional 180-day period until November 16, 2026 to meet $1.00 minimum bid price.
Initial compliance period ended May 18, 2026; company had not yet satisfied the bid price requirement.
Extension based on meeting other listing requirements and written intent to cure via reverse stock split if needed.
If not cured by new deadline, common stock may be delisted from Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an add

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-060556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.